MW 668.7 Da, Purity >90%. Z-D(OMe)E(OMe)VD(OMe)-FMK, Cell permeable caspase-3 inhibitor. Achieve your results faster with highly validated, pure and trusted compounds.
210344-95-9
> 90%
Solid
668.7 Da
C30H41FN4O12
16760394
Synthetic
A830040C14Rik, APOPAIN, CASP3_HUMAN, CC3, CPP-32, CPP32B, Casp3a, Caspase 3, apoptosis-related cysteine peptidase, Caspase 3, apoptosis-related cysteine protease, Caspase 3, apoptosis-related cysteine protease a, Caspase-3, Caspase-3 subunit p12, Cysteine protease CPP32, EC 3.4.22.56, ICE3, LICE, OTTHUMP00000165052, OTTHUMP00000165053, OTTHUMP00000165054, PARP cleavage protease, Procaspase3, Protein Yama, SCA-1, SREBP cleavage activity 1, Yama, Yama protein, mldy
MW 668.7 Da, Purity >90%. Z-D(OMe)E(OMe)VD(OMe)-FMK, Cell permeable caspase-3 inhibitor. Achieve your results faster with highly validated, pure and trusted compounds.
210344-95-9
> 90%
Solid
668.7 Da
C30H41FN4O12
16760394
Synthetic
Soluble in DMSO to 20 mM.
Z-Devd-fmk
CC(C)C(C(=O)NC(CC(=O)OC)C(=O)CF)NC(=O)C(CCC(=O)OC)NC(=O)C(CC(=O)OC)NC(=O)OCC1=CC=CC=C1
CC(C)[C@@H](C(=O)N[C@@H](CC(=O)OC)C(=O)CF)NC(=O)[C@H](CCC(=O)OC)NC(=O)[C@H](CC(=O)OC)NC(=O)OCC1=CC=CC=C1
InChI=1S/C30H41FN4O12/c1-17(2)26(29(42)33-20(22(36)15-31)13-24(38)45-4)35-27(40)19(11-12-23(37)44-3)32-28(41)21(14-25(39)46-5)34-30(43)47-16-18-9-7-6-8-10-18/h6-10,17,19-21,26H,11-16H2,1-5H3,(H,32,41)(H,33,42)(H,34,43)(H,35,40)/t19-,20-,21-,26-/m0/s1
GBJVAVGBSGRRKN-JYEBCORGSA-N
methyl (4S)-5-[[(2S)-1-[[(3S)-5-fluoro-1-methoxy-1,4-dioxopentan-3-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-[[(2S)-4-methoxy-4-oxo-2-(phenylmethoxycarbonylamino)butanoyl]amino]-5-oxopentanoate
Ambient - Can Ship with Ice
-20°C
-20°C
Store under desiccating conditions, The product can be stored for up to 12 months
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
2D chemical structure image of ab120488, Z-D(OMe)E(OMe)VD(OMe)-FMK, Cell permeable caspase-3 inhibitor
HeLa cells were incubated at 37 °C for 1h with vehicle control (0 μM) and different concentrations of Z-D(OMe)E(OMe)VD(OMe)-FMK (ab120488). After this incubation 10 μM of camptothecin (Camptothecin, DNA topoisomerase inhibitor ab120115) was added to all samples and the cells were incubated for further 24h. Increased expression of full length PARP (ab37722) in camptothecin induced apoptotic HeLA cells correlates with an increase in Z-D(OMe)E(OMe)VD(OMe)-FMK concentration, as described in literature.
Whole cell lysates were prepared with RIPA buffer (containing protease inhibitors and sodium orthovanadate), 10 μg of each were loaded on the gel and the WB was run under reducing conditions. After transfer the membrane was blocked for an hour using 5% BSA before being incubated with ab37722 at 1 μg/ml and Anti-beta Actin antibody ab8227 at 1 μg /ml overnight at 4°C. Antibody binding was detected using an anti-rabbit antibody conjugated to HRP (Goat Anti-Rabbit IgG H&L (HRP) ab97051
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com